AbbVie’s immunology portfolio, led by Skyrizi and Rinvoq, has become the engine of its near-term growth. Originally forecast to generate combined annual sales of $27 billion by 2027, management raised that target by $4 billion after both brands outperformed expectations in dermatology and rheumatology indications. Skyrizi and Rinvoq now account for more than 40% of AbbVie’s total revenue, and neither faces a patent expiration before 2031, ensuring a stable growth runway for the next five years.

Following the loss of exclusivity on its former best-seller, Humira, AbbVie successfully diversified its portfolio and now has no high-revenue drugs scheduled to lose patent protection through the end of the decade. This gap provides uninterrupted revenue visibility and buys time for the company’s R&D engine. AbbVie has completed multiple bolt-on acquisitions and licensing deals, and its pipeline features over 50 active clinical programs, including next-generation candidates in oncology and neuroscience that could help offset any future patent expirations.

AbbVie boasts more than half a century of consecutive annual dividend increases, qualifying it as a Dividend King and making it especially attractive to income-focused investors. Over the past five years, reinvested dividends contributed roughly 30% of the company’s total shareholder return, outpacing share-price gains alone. AbbVie’s board has signaled mid-single-digit payout hikes through 2031, suggesting that dividend reinvestment could meaningfully boost compounded returns over the next five years.